



Pattern genetici e Farmacoterapia

Francesco Scaglione, MD, PhD

Department of Oncology and Hemato-oncology

Postgraduate School of clinical pharmacology
University of Milan

Head of Clinical Pharmacology Unit
Niguarda - Hospital
Milan, Italy



Differente efficacia dei farmaci


Stessa malattia,
Stessi sintomi,

Stesso farmaco
Stessa dose

Stesso paziente?




Different Effects





Exogenous & Endogenous factors contribute to variation in drug response

CASO CLINICO


- **Giorno 1** - bambino maschio sano nato a termine, madre assume 30 mg di codeina / 500 mg di paracetamolo per dolore
- **Giorno 7** - difficoltà l'allattamento al seno e letargia
- **Giorno 11** - bambino, stazionario permane letargia
- **Giorno 12** - pelle grigiastra, allattamento difficoltoso
- **Giorno 13** - neonato trovato morto
- **concentrazione ematica di morfina postmortem = 70 ng/ mL**
(normale in neonati allattati al seno da madri che assumono codeina 0-2-2 ng/mL)
- **analisi genotipo CYP2D6** – madre con duplicazione genica CYP2D6 * 2x2 - metabolizzatore ultra-rapido
- i neonati generalmente hanno ridotta capacità di metabolizzare ed eliminare la morfina






- Pharmacogenetic contribution to pharmacokinetic parameters. $t_{1/2}$ of antipyrine is more concordant in identical in comparison to fraternal twin pairs. Bars show the $t_{1/2}$ of antipyrine in identical (monozygotic) and fraternal (dizygotic) twin pairs. (Redrawn from data in Vesell and Page, 1968.)

Drug therapy



DRUG METABOLIZING ENZYMES



Phase I: biotransformation reactions: oxidation, hydroxylation, reduction, hydrolysis

Phase II: conjugation reactions—to increase their water solubility and elimination from the body. The reactions are glucuronidation, sulfation, acetylation, glutathione conjugation

GENETIC VARIATION

Types of Polymorphisms

- Single Nucleotide

Polymorphism (SNP):

GAATT~~T~~AAG

GAATT~~C~~AAG

- Insertion/Deletion:

GAAAT~~T~~CCAAG


GAAA[]CCAAG

Duplicated or
multiduplicated genes



mRNA-AAAAA
mRNA-AAAAA
mRNA-AAAAA

Higher
enzyme levels




Increased
metabolism

CYP2D6*2xN

Pharmacogenetics

- **Definition:** how genes affect the way people respond to drug therapy.




I pazienti rispondono in modo differente ai farmaci

“One size does not fit all ...”


- 😊 Toxic responders
- 😐 Non-responders
- 😃 Responders




Patient population with same
disease phenotype



Genetic Polymorphisms: Drug Concentration and Drug Effect



Treatment Modifications and Patient Genotypes



Common pain medications

Pain Management

Drug	Metabolic Route	Drug	Metabolic Route
Alfentanil	CYP3A4/CYP3A5	Lidocaine	CYP1A2
Carisoprodol**	CYP2C19	Methadone	CYP2C19, CYP2B6 ⁺
Celecoxib	CYP2C9	Morphine	UGT2B7 ⁺ (OPRM1)
Codeine**	CYP2D6	Naproxen	CYP2C9
Cyclobenzaprine	CYP1A2, CYP3A4/CYP3A5	Oxycodone**	CYP2D6, CYP3A4/5
Fentanyl	CYP3A4/CYP3A5	Oxymorphone	UGT2B7 ⁺ (OPRM1)
Hydrocodone**	CYP2D6	Ropivacaine	CYP1A2
Hydromorphone	UGT2B7	Tizanidine	CYP1A2
Ibuprofen	CYP2C9	Tramadol**	CYP2D6
**prodrug;		Zolmitriptan	CYP1A2

LIMITI della farmacogenetica

- Targeting complesso se coinvolgimento di più geni
- Difficile e richiede tempo per identificare variazioni di geni poco noti
- Interazione con altri farmaci e ambiente da determinare

Barriere della farmacogenetica

- Scarsità di laboratori di farmacogenetica
- Scarsa esperienza nei clinici
- Pochi farmacologi clinici con esperienza nell'adattamento della dose

Personalized medicine


"Here is my sequence"



- Grazie

Determinants of Drug Efficacy and Toxicity

A patient's response to a drug may depend on factors that can vary according to the alleles that an individual carries, including :



➤ Pharmacokinetic factors

- Absorption
- Distribution
- Metabolism
- Elimination

➤ Pharmacodynamic factors

- Target proteins
- Downstream messengers